Included in the formulation
АТХ:L.03.A Cytokines and immunomodulators
Pharmacodynamics:Induction of interferon synthesis, stimulation of phagocytosis, increase of resistance of the organism to infections. The drug is active against certain viruses and chlamydia.
Pharmacokinetics:When topical application is rapidly absorbed and distributed in organs and tissues with the participation of the endolymphatic pathway. In the phase of intensive drug delivery to the blood, a redistribution occurs between the plasma and the formed elements of the blood, in parallel with the metabolism and excretion.
Metabolised in the body. The final metabolites are xanthine, hypoxanthine, beta-alanine, acetic, propionic and uric acids, which are excreted from the gastrointestinal tract.
Excreted from the body (in the form of metabolites) by the kidneys by bi-exponential dependence and, in part, through the gastrointestinal tract.
Indications:- Primary, late radiation ulcers and thermal skin burns of II-III severity;
- Acute radial pharyngeal syndrome;
- trophic ulcers;
- violation of the integrity of the mucous membrane of the oral cavity, nose, vagina, rectum;
- Decubital ulcers in the oral cavity and on the skin;
- complications associated with cytotoxic therapy (stomatitis, pharyngo esophagitis, gingivitis, uvulitis, enterocolitis, vulvovaginitis, paraproctitis);
- when preparing tissues for auto- or allotransplantation and during transplant engraftment.
IX.I80-I89.I83.0 Varicose veins of the lower extremities with ulcer
XII.L55-L59.L58 Radiation dermatitis radiation
XII.L80-L99.L89 Decubital ulcer
XIX.T20-T32.T30 Thermal and chemical burns, unspecified
XXI.Z80-Z99.Z94 Presence of transplanted organs and tissues
Contraindications:Hypersensitivity to sodium deoxyribonucleate or any other component of the drug.
Pregnancy and lactation:Adequate and well-controlled studies in humans and animals have not been conducted. Contraindicated. There is no information on the penetration into breast milk.
Category of recommendations FDA is not defined.
Dosing and Administration:The drug is prescribed children from the first day of life and adults.
For treatment skin lesions impose application dressings with a solution of the drug, followed 3-4 times a day.
When lesions of the oral mucosa Rinses are made by a solution of sodium ribonucleate (4 times a day for 5-15 ml withby swallowing).
In the vagina sodium ribonucleate is introduced on a swab, in the rectum - in an enema (20-50 ml).
The duration of the course of treatment is until the signs of inflammation and epithelization of the skin and mucous membranes disappear persistently (4-10 days).
Side effects:Allergic reactions.
Interaction:Not described.
Special instructions:The drug should be stored at a temperature from -12 ° C to + 8 ° C, out of the reach of children.